文献速递慢阻肺

再入院削减计划对慢阻肺患者再入院与死亡率的影响

Readmissions Reduction Program: Mortality and Readmissions for Chronic Obstructive Pulmonary Disease.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

该回顾性队列研究分析了2006至2017年N=4,587,542例65岁以上医保慢阻肺住院患者,评估HRRP实施与30天再入院及出院后死亡率的关联。结果显示30天再入院率从20.54%降至18.74%,但HRRP实施期30天风险标化出院后死亡率升高,估计额外死亡1,196例和3,858例。

要点

  • HRRP实施期慢阻肺30天再入院率从20.54%降至18.74%
  • 实施期30天风险标化出院后死亡率升至7.30%
  • HRRP实施与出院后30天死亡率显著增加相关

核心结论

  • HRRP实施期30天全因再入院率较预公告期下降。
  • HRRP实施与慢阻肺出院后30天死亡率显著增加相关。

研究设计与样本

  • 回顾性队列研究,纳入2006至2017年N=4,587,542例65岁及以上医保按服务付费慢阻肺住院患者。

主要发现

  • 30天风险标化出院后死亡率在预公告期、公告期和实施期分别为6.91%、6.59%和7.30%。
  • 广义估计方程分析估计实施期额外死亡1,196例(2014年10月至2016年4月)和3,858例(2016年5月至2017年11月)。

临床怎么用

  • 临床需关注HRRP实施背景下慢阻肺患者出院后死亡风险可能增加。
  • 再入院率下降的同时应监测出院后30天死亡率变化。

局限性

  • 需进一步研究确认 findings 并理解HRRP实施期慢阻肺死亡率增加的 contributing 因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Implementation of the Hospital Readmissions Reduction Program (HRRP) following discharge of patients with chronic obstructive pulmonary disease (COPD) has led to a reduction in 30-day readmissions with unknown effects on postdischarge mortality.Objectives: To examine the association of HRRP with 30-day hospital readmission and 30-day postdischarge mortality rate in patients after discharge from COPD hospitalization.Methods: Retrospective cohort study of readmission and mortality rates in a national cohort (N = 4,587,542) of admissions of Medicare fee-for-service beneficiaries 65 years or older with COPD from 2006 to 2017.Measurements and Main Results: Data were analyzed for three nonoverlapping periods based on implementation of the HRRP specific to COPD: 1) preannouncement (December 2006 to March 2010), 2) announcement (April 2010 to August 2014), and 3) implementation (October 2014 to November 2017). The 30-day readmission rate decreased from 20.54% in the preannouncement period (December 2006 to July 2008) to 18.74% in the implementation period (May 2016 to November 2017). The 30-day risk-standardized postdischarge mortality rates were 6.91%, 6.59%, and 7.30% for the preannouncement, announcement, and implementation periods, respectively. Generalized estimating equations analyses estimated an additional 1,196 deaths (October 2014 to April 2016) and 3,858 deaths (May 2016 to November 2017) during the HRRP implementation period.Conclusions: We found a reduction in 30-day all-cause readmission rate during the implementation period compared with the preannouncement phase. HRRP implementation was also associated with a significant increase in 30-day mortality after discharge from COPD hospitalization. Additional research is necessary to confirm our findings and understand the factors contributing to increased mortality in patients with COPD in the HRRP implementation period.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Puebla Neira DA, Hsu ES, Kuo YF, et al. Readmissions Reduction Program: Mortality and Readmissions for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021. PMID: 32871097. doi:10.1164/rccm.202002-0310OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。